Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
We report 5-year visual and anatomical outcomes after combination therapy of photodynamic therapy (PDT) and intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy (PCV) and predictive factors for visual outcomes at 5-year and time to recurrence. Medical charts wer...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0229231 |
| _version_ | 1818579380756021248 |
|---|---|
| author | Kikushima Wataru Atsushi Sugiyama Seigo Yoneyama Mio Matsubara Yoshiko Fukuda Ravi Parikh Yoichi Sakurada |
| author_facet | Kikushima Wataru Atsushi Sugiyama Seigo Yoneyama Mio Matsubara Yoshiko Fukuda Ravi Parikh Yoichi Sakurada |
| author_sort | Kikushima Wataru |
| collection | DOAJ |
| description | We report 5-year visual and anatomical outcomes after combination therapy of photodynamic therapy (PDT) and intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy (PCV) and predictive factors for visual outcomes at 5-year and time to recurrence. Medical charts were retrospectively reviewed for 43 consecutive eyes with PCV treated with combination therapy of PDT and intravitreal injection of ranibizumab(n = 13) or aflibercept(n = 30) and completed 5-year follow-up. The variants of ARMS2 A69S and CFH I62V were genotyped using TaqMan assay. Best corrected visual acuity (BCVA) significantly improved at 5-year (P = 0.01) with 20% reduction of subfoveal choroidal thickness irrespective of presence or absence of recurrence. Visual improvement was associated with baseline shorter greatest linear dimension (GLD) (P = 1.0×10-4). Mean time to recurrence was 28.6±23.1 months (95% CI: 21.5-35.7, Median:18.0) and time to recurrence was associated with G allele (protective allele) of ARMS2 A69S and GLD (P = 4.0×10-4 and 1.0×10-2, respectively). Multiple regression analysis revealed that time to recurrence extended by 15.5 months when the G allele of ARMS2 A69S increased by one allele (TT: 15.7±17.0, TG: 30.8±23.5, GG: 41.1±22.6 months). The combination therapy resulted in a favorable visual outcome for PCV during 5-year follow-up. |
| first_indexed | 2024-12-16T07:00:47Z |
| format | Article |
| id | doaj.art-ba7282aa40644cceb1dc1dad6521b0a2 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T07:00:47Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ba7282aa40644cceb1dc1dad6521b0a22022-12-21T22:40:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01152e022923110.1371/journal.pone.0229231Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.Kikushima WataruAtsushi SugiyamaSeigo YoneyamaMio MatsubaraYoshiko FukudaRavi ParikhYoichi SakuradaWe report 5-year visual and anatomical outcomes after combination therapy of photodynamic therapy (PDT) and intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy (PCV) and predictive factors for visual outcomes at 5-year and time to recurrence. Medical charts were retrospectively reviewed for 43 consecutive eyes with PCV treated with combination therapy of PDT and intravitreal injection of ranibizumab(n = 13) or aflibercept(n = 30) and completed 5-year follow-up. The variants of ARMS2 A69S and CFH I62V were genotyped using TaqMan assay. Best corrected visual acuity (BCVA) significantly improved at 5-year (P = 0.01) with 20% reduction of subfoveal choroidal thickness irrespective of presence or absence of recurrence. Visual improvement was associated with baseline shorter greatest linear dimension (GLD) (P = 1.0×10-4). Mean time to recurrence was 28.6±23.1 months (95% CI: 21.5-35.7, Median:18.0) and time to recurrence was associated with G allele (protective allele) of ARMS2 A69S and GLD (P = 4.0×10-4 and 1.0×10-2, respectively). Multiple regression analysis revealed that time to recurrence extended by 15.5 months when the G allele of ARMS2 A69S increased by one allele (TT: 15.7±17.0, TG: 30.8±23.5, GG: 41.1±22.6 months). The combination therapy resulted in a favorable visual outcome for PCV during 5-year follow-up.https://doi.org/10.1371/journal.pone.0229231 |
| spellingShingle | Kikushima Wataru Atsushi Sugiyama Seigo Yoneyama Mio Matsubara Yoshiko Fukuda Ravi Parikh Yoichi Sakurada Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLoS ONE |
| title | Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. |
| title_full | Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. |
| title_fullStr | Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. |
| title_full_unstemmed | Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. |
| title_short | Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. |
| title_sort | five year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy |
| url | https://doi.org/10.1371/journal.pone.0229231 |
| work_keys_str_mv | AT kikushimawataru fiveyearoutcomesofphotodynamictherapycombinedwithintravitrealinjectionofranibizumaborafliberceptforpolypoidalchoroidalvasculopathy AT atsushisugiyama fiveyearoutcomesofphotodynamictherapycombinedwithintravitrealinjectionofranibizumaborafliberceptforpolypoidalchoroidalvasculopathy AT seigoyoneyama fiveyearoutcomesofphotodynamictherapycombinedwithintravitrealinjectionofranibizumaborafliberceptforpolypoidalchoroidalvasculopathy AT miomatsubara fiveyearoutcomesofphotodynamictherapycombinedwithintravitrealinjectionofranibizumaborafliberceptforpolypoidalchoroidalvasculopathy AT yoshikofukuda fiveyearoutcomesofphotodynamictherapycombinedwithintravitrealinjectionofranibizumaborafliberceptforpolypoidalchoroidalvasculopathy AT raviparikh fiveyearoutcomesofphotodynamictherapycombinedwithintravitrealinjectionofranibizumaborafliberceptforpolypoidalchoroidalvasculopathy AT yoichisakurada fiveyearoutcomesofphotodynamictherapycombinedwithintravitrealinjectionofranibizumaborafliberceptforpolypoidalchoroidalvasculopathy |